Gastrointestinal Cancer News

The addition of bevacizumab to modied FOLFOX6 improved liver metastases resection rates and survival outcomes among certain patients with colorectal liver metastases, according to study results published in Journal of Clinical Oncology.

About 12% of elective colonoscopies during a recent 5-year period led to out-of-network claims that averaged hundreds of dollars more than the typical insurance payment, data in Annals of Internal Medicine show.

Positive results from a phase 2 study of a three-drug regimen to treat biliary tract cancer paved the way for the first randomized phase 3 study of its kind in the U.S., led by Rachna Shroff, MD, MS.

Pamela Kunz, MD, is an expert in GI cancers and a courageous voice against gender discrimination and harassment in health care. In this episode, Kunz shares her story and provides guidance for those facing these types of challenges.

The FDA granted orphan drug designation to CT041 for the treatment of adults with relapsed or refractory gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, according to the agent’s manufacturer.

Although testing for microsatellite instability and mismatch repair deficiency has increased for advanced colorectal cancer, substantial gaps in testing remain among certain patient groups, according to study results.

Deirdre J. Cohen, MD, MS, has been appointed director of the gastrointestinal oncology program at Mount Sinai Health System.

The number of newly identified patients with six common types of cancer declined significantly soon after the COVID-19 pandemic began, according to data in a research letter published in JAMA Network Open.

Residents of U.S. counties that experience persistent poverty appear to be at a disproportionally higher risk for cancer mortality than residents of other counties, including those experiencing current poverty, according to study findings.

Adjuvant nivolumab significantly prolonged DFS compared with placebo among patients with resected esophageal and gastroesophageal junction cancer, according to results of the CheckMate 577 trial presented during ESMO Virtual Congress 2020.